Recent Updates — APM

The Board of Directors appointed Thomas Freeburg as Chief Financial Officer, effective September 1, 2026. Mr. Freeburg will receive a base salary of $250,000, an annual bonus up to 50% of base, and 50,000 stock options with an exercise price of $8.83 per share. The appointment is for a two-year term at the Board's discretion. Niki BioSolutions operates in the biotechnology sector.

Niki BioSolutions, Inc. entered into an At the Market Offering Agreement with H.C. Wainwright & Co., LLC and Brookline Capital Markets on October 9, 2026. The agreement allows the company to sell shares of its common stock from time to time through these sales agents for an aggregate maximum offering price of up to $1,396,000. H.C. Wainwright will act as the primary sales agent, while Brookline Capital Markets serves as a qualified independent underwriter to address conflicts of interest involving Wainwright's managing director who is also a company director and shareholder. The company pays a 3% placement fee on gross sales price and may terminate the agreement with ten business days' notice. Niki BioSolutions operates in the biotechnology sector, focusing on developing biotherapeutics.

Aptorum Group Limited redomiciled as Niki BioSolutions, Inc. and completed its merger with DiamiR Biosciences Corp. on July 20, 2026. The transaction involved a 1-for-10 reverse stock split of Aptorum's authorized share capital. Niki BioSolutions, Inc. is a biopharmaceutical company focused on therapeutic assets for oncology and infectious diseases.

Aptorum Group Limited and DiamiR Biosciences Corp. have agreed to extend the termination date for their merger agreement, management services agreement, and intellectual property license agreement to July 31, 2026. This extension is intended to satisfy closing conditions for the merger. Aptorum Group Limited is a biotechnology company focused on therapeutic development.

Aptorum Group Limited shareholders approved five proposals at an extraordinary general meeting on June 9, 2026, including the domestication of the company from the Cayman Islands to Delaware and a merger with DiamiR Biosciences Corp. Other approved items include a share consolidation at a ratio to be determined by the Board (between 2-1 and 10-1), the issuance of shares to DiamiR stockholders, a new stock incentive plan with 4.5 million shares, and the appointment of five new directors. The company operates in the biotechnology industry, focusing on the development of therapeutic treatments.